Cargando…

Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients

Approximately 45% of metastatic colorectal cancer (mCRC) patients with wild-type KRAS exon 2 are resistant to cetuximab treatment. We set out to identify additional genetic markers that might predict the response to cetuximab treatment. Fifty-three wild-type KRAS exon 2 mCRC patients were treated wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsu, Hung-Chih, Thiam, Tan Kien, Lu, Yen-Jung, Yeh, Chien Yuh, Tsai, Wen-Sy, You, Jeng Fu, Hung, Hsin Yuan, Tsai, Chi-Neu, Hsu, An, Chen, Hua-Chien, Chen, Shu-Jen, Yang, Tsai-Sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008360/ https://www.ncbi.nlm.nih.gov/pubmed/26989027 http://dx.doi.org/10.18632/oncotarget.8076

Ejemplares similares

TP53 DNA Binding Domain Mutations Predict Progression-Free Survival of Bevacizumab Therapy in Metastatic Colorectal Cancer
por: Hsu, Hung-Chih, et al.
Publicado: (2019)

PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients
por: Hsu, Hung-Chih, et al.
Publicado: (2018)

Effect of KRAS and NRAS mutations on the prognosis of patients with synchronous metastatic colorectal cancer presenting with liver-only and lung-only metastases
por: Chuang, Shih-Chang, et al.
Publicado: (2020)

Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild‐type KRAS exon 2 metastatic colorectal cancer
por: Hsu, Hung‐Chih, et al.
Publicado: (2019)

A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAF(V600) wild-type colorectal cancer
por: Georgiou, Alexandros, et al.
Publicado: (2021)

Phase II Single-Arm Study of Palbociclib and Cetuximab Rechallenge in Patients with KRAS/NRAS/BRAF Wild-Type Colorectal Cancer
por: Sorah, Jonathan D, et al.
Publicado: (2022)

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma
por: Pasca, Sergiu, et al.
Publicado: (2019)

Molecular Pattern and Clinical Implications of KRAS/NRAS and BRAF Mutations in Colorectal Cancer
por: Gökmen, İvo, et al.
Publicado: (2023)

KRAS, NRAS, and BRAF mutations in plasma cell myeloma at a single Korean institute
por: Kim, Yonggoo, et al.
Publicado: (2020)

KRAS/NRAS/BRAF Mutation Rate in Saudi Academic Hospital Patients With Colorectal Cancer
por: Saharti, Samah
Publicado: (2022)

High prevalence of unusual KRAS, NRAS, and BRAF mutations in POLE ‐ hypermutated colorectal cancers
por: Favre, Loetitia, et al.
Publicado: (2022)

KRAS, NRAS, BRAF signatures, and MMR status in colorectal cancer patients in North China
por: Lian, Shen-Yi, et al.
Publicado: (2023)

KRAS, NRAS, BRAF, HER2 and Microsatellite Instability in Metastatic Colorectal Cancer – Practical Implications for the Clinician
por: Afrăsânie, Vlad-Adrian, et al.
Publicado: (2019)

Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer
por: Bożyk, Aleksandra, et al.
Publicado: (2021)

Short- and medium-term outcomes of intracorporeal versus extracorporeal anastomosis in laparoscopic right colectomy: a propensity score-matched study
por: Liao, Chun-Kai, et al.
Publicado: (2021)

Continuing Cetuximab vs Bevacizumab plus chemotherapy after first progression in wild-type KRAS, NRAS and BRAF V600E metastatic colorectal cancer: a randomized phase II trial
por: Li, Danyang, et al.
Publicado: (2021)

Impact of microsatellite status on chemotherapy for colorectal cancer patients with KRAS or BRAF mutation
por: Huang, Chi-Jung, et al.
Publicado: (2016)

KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study
por: Negru, Serban, et al.
Publicado: (2014)

Mutation Status and Immunohistochemical Correlation of KRAS, NRAS, and BRAF in 260 Chinese Colorectal and Gastric Cancers
por: Yang, Qiwei, et al.
Publicado: (2018)

Evaluation of KRAS, NRAS and BRAF mutations detection in plasma using an automated system for patients with metastatic colorectal cancer
por: Franczak, Claire, et al.
Publicado: (2020)

Detection of KRAS, NRAS and BRAF by mass spectrometry - a sensitive, reliable, fast and cost-effective technique
por: Kriegsmann, Mark, et al.
Publicado: (2015)

KRAS, NRAS, BRAF, HER2 and MSI Status in a Large Consecutive Series of Colorectal Carcinomas
por: Martianov, Aleksandr S., et al.
Publicado: (2023)

Genomic Profiling for KRAS, NRAS, BRAF, Microsatellite Instability, and Mismatch Repair Deficiency Among Patients With Metastatic Colon Cancer
por: Gutierrez, Martin E., et al.
Publicado: (2019)

Circulating Tumor Cell Count Correlates with Colorectal Neoplasm Progression and Is a Prognostic Marker for Distant Metastasis in Non-Metastatic Patients
por: Tsai, Wen-Sy, et al.
Publicado: (2016)

Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients
por: Guo, Fang, et al.
Publicado: (2018)

Pharmacological Activation Of Aldehyde Dehydrogenase 2 Protects Against Heatstroke-Induced Acute Lung Injury by Modulating Oxidative Stress and Endothelial Dysfunction
por: Tsai, Hsiao-Ya, et al.
Publicado: (2021)

Usefulness of close surveillance for rectal cancer patients after neoadjuvant chemoradiotherapy
por: Hsu, Yu-Jen, et al.
Publicado: (2022)

A Systematic Literature Review and Meta-Analysis Describing the Prevalence of KRAS, NRAS, and BRAF Gene Mutations in Metastatic Colorectal Cancer
por: Levin-Sparenberg, Elizabeth, et al.
Publicado: (2020)

Accurate detection of KRAS, NRAS and BRAF mutations in metastatic colorectal cancers by bridged nucleic acid-clamp real-time PCR
por: Nagakubo, Yuki, et al.
Publicado: (2019)

Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer
por: Takahashi, Naoki, et al.
Publicado: (2014)

Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance
por: Módos, Orsolya, et al.
Publicado: (2016)

Frequency of NRAS Gene Mutation in Wild Type KRAS and BRAF Colorectal Cancers; a Single Center Study
por: Momenzadeh, Hooria, et al.
Publicado: (2018)

A Prediction Model for Metachronous Peritoneal Carcinomatosis in Patients with Stage T4 Colon Cancer after Curative Resection
por: Tsai, Tzong-Yun, et al.
Publicado: (2021)

ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours
por: Segelov, Eva, et al.
Publicado: (2016)

Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol
por: Chen, Shang-Hung, et al.
Publicado: (2019)

The predictive value of KRAS and NRAS mutations in metastatic colorectal cancer
por: Eshraghi, Abbas, et al.
Publicado: (2020)

Atypical BRAF and NRAS Mutations in Mucosal Melanoma
por: Dumaz, Nicolas, et al.
Publicado: (2019)

Association of Preoperative Physical Activity with Short- and Long-Term Outcomes in Patients Undergoing Palliative Resection for Metastatic Colorectal Cancer: An Inverse Probability of Treatment Weighting Analysis
por: Cheng, Ching-Chung, et al.
Publicado: (2022)

Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation
por: Lionetti, Marta, et al.
Publicado: (2015)

Construction of a reference material panel for detecting KRAS/NRAS/EGFR/BRAF/MET mutations in plasma ctDNA
por: Xu, Jun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qnhst2mssupot5dekpm1f19sce